Durvalumab Approval Withdrawn for Urothelial Carcinoma

Today, AstraZeneca voluntarily withdrew the indication of durvalumab (Imfinzi®, AstraZeneca) for patients with previously treated locally advanced or metastatic urothelial carcinoma based on results of the phase 3 DANUBE trial (NCT02516241), which did not meet its primary end points. The withdrawal does not affect durvalumab's indications for non-small cell lung cancer or for extensive stage small-cell lung cancer. Durvalumab, a human monoclonal antibody that binds to programmed death ligand 1 (...

Stage I Seminoma: Post-Orchiectomy MRI Surveillance Noninferior to CT

For patients with stage I seminoma, a germ cell tumor of the testicle or other extragonadal locations, post-orchiectomy surveillance with magnetic resonance imaging (MRI) is noninferior to computed tomography (CT) imaging and avoids excess radiation, according to results of the phase 3 Trial of Imaging and Surveillance in Seminoma Testis (TRISST) presented this past weekend at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. "Survival after orchiectomy in stage I...

Lenvatinib/Pembrolizumab Improves Survival in Renal Cell Carcinoma

Results from a phase 3 trial of patients with advanced renal cell carcinoma (RCC) presented this week at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium and simultaneously published in The New England Journal of Medicine demonstrated that the first-line treatment regimen of lenvatinib, a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, plus pembrolizumab, an anti–programmed cell death protein 1 (PD-1) monoclonal antibody, lengthened ...

Advanced Renal Cell Carcinoma: Nivolumab/Cabozantinib Approved

The FDA has approved nivolumab (Opdivo®, Bristol Myers Squibb) in combination with cabozantinib (Cabometyx®, Exelixis) for patients with advanced renal cell carcinoma (RCC) receiving their first line of therapy. "As monotherapies, nivolumab and cabozantinib have demonstrated efficacy and a manageable safety profile in advanced RCC," wrote Toni Choueiri, MD, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, and colleagues in their abstract of results from the...

Renal Cell Carcinoma: Subtype, Site of Metastasis Impacts Survival

There are over a dozen histologic variants of renal cell carcinoma (RCC); therefore, each tumor can vary widely based on genetic, pathologic, and clinical characteristics. The most common histologic variants of RCC include clear cell RCC, papillary RCC, and chromophobe RCC. In a recent study, results of which are now published in JAMA Network Open, researchers found that disease spread for metastatic RCC may vary based on histologic variant, and the location of disease spread is associated with ...

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.

Cron Job Starts